Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies Journal Article

Local Library Link: Find It @ Loyola

Authors: Soriano, M. M.; Danziger, L. H.; Gerding, D. N.; Johnson, S
Article Title: Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
Abstract: Reports of fidaxomicin treatment for patients with multiple recurrent Clostridium difficile infections ([mrCDI] ie, more than 2 CDI episodes) indicate symptomatic response to this agent, but 50% have subsequent mrCDI episodes. In an effort to improve outcomes in patients with mrCDI we used novel regimens of fidaxomicin based on strategies used with vancomycin. Of 8 patients who received a 10-day chaser of fidaxomicin given twice daily after a course of vancomycin, 3 (38%) experienced a subsequent recurrence. Two (18%) of 11 patients who completed a 14- to 33-day course of fidaxomicin in a tapering dose experienced a recurrence, both of whom received additional antibiotics before that recurrence. The median symptom-free interval (SFI) after fidaxomicin taper was greater than the median SFI after the most effective prior regimen for those patients (257 days [interquartile range, 280] vs 25 days [interquartile range, 30], respectively; P = .003). A fidaxomicin chaser or taper regimen may be effective in patients with mrCDI, but the number of patients treated is small, and randomized comparative data are not available.
Journal Title: Open forum infectious diseases
Volume: 1
Issue: 2
ISSN: 2328-8957; 2328-8957
Publisher: Unknown  
Journal Place: United States
Date Published: 2014
Start Page: ofu069
Language: eng
DOI/URL:

10.1093/ofid/ofu069
Notes: LR: 20150305; JID: 101637045; OID: NLM: PMC4281782; OTO: NOTNLM; 2014/09 [ecollection]; 2014/06/11 [received]; 2014/07/23 [accepted]; 2014/08/25 [epublish]; epublish